Back to top
more

Dipexium Pharmaceuticals, Inc. (PLXP)

(Delayed Data from NSDQ)

$5.62 USD

5.62
4,821

+0.20 (3.76%)

Updated May 3, 2019 04:13 PM ET

After-Market: $5.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Dipexium Pharmaceuticals (PLXP) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Dipexium Pharmaceuticals (PLXP) stock based on the movements in the options market lately.

Is a Surprise Coming for PLx Pharma (PLXP) This Earnings Season?

by Zacks Equity Research

PLx Pharma (PLXP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Shrabana Mukherjee headshot

New Analyst Coverage Puts Spotlight on These 4 Stocks

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Guess' (GES), Babcock (BW), Wabash (WNC) and PLx Pharma (PLXP).

Earnings Preview: PLx Pharma (PLXP) Q2 Earnings Expected to Decline

by Zacks Equity Research

PLx Pharma (PLXP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLx Pharma (PLXP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

PLx Pharma (PLXP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.